Company Statement on US-FDA Inspection at Biocon Malaysia

  • Posted by: Biocon Biologics

21st February 2018

“The US-FDA has completed a pre-approval inspection of our manufacturing facility in Malaysia and issued a Form 483 with 6 observations. As per the normal expectations of the agency, we intend to respond with a corrective and preventive action plan in a timely manner.” – Biocon Spokesperson.

Author: Biocon Biologics
buy twitter followers